Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 11, Number 6—June 2005
Research

Community-associated Methicillin-resistant Staphylococcus aureus, Canada

Michael R. Mulvey*Comments to Author , Laura MacDougall†‡, Brenda Cholin§, Greg Horsman¶, Melanie Fidyk#, Shirley Woods**, and the Saskatchewan CA-MRSA Study Group
Author affiliations: *National Microbiology Laboratory, Winnipeg, Manitoba, Canada; †British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada; ‡Health Canada, Ottawa, Ontario, Canada; §Prairie North Health Region, North Battleford, Saskatchewan, Canada; ¶Saskatchewan Health Provincial Laboratory, Regina, Saskatchewan, Canada; #Kelsey Trail Health Region, Nipawin, Saskatchewan, Canada; **Northern Intertribal Health Authority, Prince Albert, Saskatchewan, Canada

Main Article

Table 2

Antimicrobial susceptibilities of the different clonal groups identified using pulsed-field gel electrophoresis

Antimicrobial agent Clonal group A (n = 55)
 Clonal group B (n = 126)
MIC50 (mg/L) MIC90 (mg/L) % resistant Range MIC50 (mg/L) MIC90 (mg/L) % resistant Range
Oxacillin 16 32 100 4–64 16 32 100 4–64
Cefazolin 32 32 75 4–32 16 32 31 2–32
Ciprofloxacin 32 ≥32 86 0.25–≥32 0.25 0.25 0 0.25–0.5
Clindamycin <0.25 ≥8 11 <0.25–≥8 <0.25 <0.25 1.6 <0.25–≥8
Erythromycin >8 ≥8 87 <0.25–≥8 <0.25 ≥8 40 <0.25–≥8
Gentamicin >16 ≥16 64 <0.5–≥16 <0.5 <0.5 0 <0.5
Rifampin <0.25 <0.25 3.6 <0.25–≥4 <0.25 <0.25 0 <0.25
Tetracycline 16 ≥16 55 <2–≥16 <2 <2 0 <2
Trimethoprim/sulfamethoxazole <0.25 0.5 5.5 <0.25 <0.25 <0.25 0 <0.25
Vancomycin 1.0 1.0 0 1.0 1.0 1.0 0 0.5-1.0
Linezolid 4.0 4.0 0 4.0 2.0 4.0 0 1.0-4.0
Mupirocin ≥128 ≥128 58 ≥128 ≥128 ≥128 55.6 <0.25–≥128
Fusidic acid ≥8 ≥8 100 ≥8.0 0.12 0.25 0 0.12–0.25

Main Article

1Members of the Saskatchewan CA-MRSA Study Group: N. Antonishyn, Provincial Laboratory Saskatchewan Health, Regina, SK; T. Du, National Microbiology Laboratory, Winnipeg, MB; J. Embil, University of Manitoba, Winnipeg, MB; A. Graessli, University of Manitoba, Winnipeg, MB; J. Irvine, Keewatin Yatthe & Mamaweetan Churchill Regional Health Authority, La Ronge, SK; M. Khan, Kelsey Trail Health Region, Melfort, SK; S. Martin, Kelsey Trail Health Region, Nipawin, SK; R. McDonald, Provincial Laboratory Saskatchewan Health, Regina, SK; M. Nsungu, Northern Intertribal Health Authority, Prince Albert, SK; S. Paton, Public Health Agency of Canada, Ottawa, ON; C. Celin, National Microbiology Laboratory, Winnipeg, MB; D. Spreitzer, National Microbiology Laboratory, Winnipeg, MB; D. Stockdale, Keewatin Yatthe & Mamaweetan Churchill Regional Health Authority, La Ronge, SK.

Page created: April 24, 2012
Page updated: April 24, 2012
Page reviewed: April 24, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external